Related Experiment Video

Updated: Jun 1, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment

Yi-Fan Zhao1, Chong-Ren Wang, Yan-Ming Wu

  • 1Laboratory of Cancer Research, Tongji University School of Medicine, Shanghai 200092, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|May 28, 2011
PubMed

Insights

Gefitinib halts non-small cell lung cancer (NSCLC) cell growth by increasing p21 stability, leading to G1 arrest. Beta-elemene restores Gefitinib sensitivity in resistant NSCLC by modulating p21 levels.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer is a leading global cause of cancer mortality.
  • Gefitinib, an EGFR tyrosine kinase inhibitor, is used for non-small cell lung cancer (NSCLC) treatment.
  • Acquired resistance to Gefitinib is a significant clinical challenge in NSCLC.

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying Gefitinib's antitumor effects in NSCLC.
  • To investigate the role of p21 in Gefitinib sensitivity and resistance.
  • To explore beta-elemene as a potential sensitizer for Gefitinib-resistant NSCLC.

Main Methods:

  • Cell-based assays to assess cell cycle progression and protein levels (p-Akt, p21, cdk2/4, cyclinE/D1).
  • Analysis of Gefitinib-induced p21 changes, focusing on protein stability versus RNA accumulation.
  • In vitro studies combining Gefitinib with beta-elemene in Gefitinib-resistant NSCLC cells.
  • p21 overexpression and knockdown experiments to confirm its role.

Main Results:

  • Gefitinib induced G1 arrest in sensitive NSCLC cells by reducing p-Akt and increasing p21 levels, while suppressing cdk2/4 and cyclinE/D1 activities.
  • Elevated p21 levels were primarily due to increased protein stability, not RNA accumulation.
  • Beta-elemene treatment restored Gefitinib sensitivity in resistant NSCLC cells by modulating p21 levels.
  • p21 was confirmed as essential for Gefitinib sensitivity through overexpression and knockdown studies.

Conclusions:

  • p21 is a critical mediator of Gefitinib sensitivity in NSCLC.
  • Gefitinib's efficacy involves p21 stabilization and subsequent cell cycle arrest.
  • Combination therapy with Gefitinib and beta-elemene shows promise for overcoming Gefitinib resistance in NSCLC.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...